FIELD: chemistry.
SUBSTANCE: invention relates to compounds of general formula (I) and their acid-additive and basic salts as FAAH enzyme inhibitors, method of producing said compounds, a pharmaceutical composition based on said compounds and their use, as well as to intermediate compounds of formula (IIa). In general formula (I) 
, m is an integer ranging from 1 to 4; n is equal to 1 or 2; o is equal to 1 or 2; A is selected from one or several groups X, Y; X denotes a methylene group optionally substituted with one group which is C1-6-alkyl; Y denotes a C2-alkynylene group; B denotes a covalent bond or C1-6-alkylene group; G denotes a covalent bond, an oxygen atom; R1 denotes an R4 group optionally substituted with one or more R5 and/or R6 groups; R4 denotes a group selected from oxazolyl, isoxazolyl, thiazolyl, phenyl, pyridinyl, naphthyl, quinolinyl, isoquinolinyl; R5 denotes a halogen atom, a cyano group, C1-6-alkyl, C1-6-alkoxy, C1-6-fluoroalkyl, C1-6-fluroalkoxy, NR7R8; R6 denotes a phenyl group, phenyloxy or pyrimidinyloxy; where R6 group(s) can be substituted with one or two R5 groups which are identical or different from each other; R7 and R8 independently denote a C1-6-alkyl group; R2 denotes a hydrogen atom; R3 denotes a hydrogen atom or C1-C6-alkyl group. In general formula (IIa) 
, m is an integer ranging from 1 to 2; n equals 2, o equals 2; A denotes X, X denotes a methylene group; B denotes a C1-6-alkylene group; G denotes a covalent bond; R1 denotes an R4 group optionally substituted with one or more R5 and/or R6 groups; R4 denotes phenyl; R5 denotes a halogen atom, C1-6alkoxy; R6 denotes a phenyl group; R2 denotes a hydrogen atom.
EFFECT: compounds can be used for treating and preventing diseases mediated by FAAH enzyme activity, such as acute and chronic pain, dizziness, vomiting, nausea, disrupted eating behaviour, neurologic and psychiatric pathologies, acute and chronic neurodegenerative diseases etc.
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROARYLALKYLCARBAMATE DERIVATIVES, THEIR OBTAINING AND THEIR APPLICATION AS ENZYME FAAH INHIBITORS | 2005 |
|
RU2364586C2 |
| DERIVATIVES OF ARYL- AND HETEROARYLPIPERIDINECARBOXYLATES, THEIR PRODUCTION AND THEIR USE AS INHIBITORS OF FAAH FERMENT | 2005 |
|
RU2376305C2 |
| ARYLOXYALKYLCARBAMATE DERIVATIVES, SYNTHESIS THEREOF AND USE IN THERAPY | 2005 |
|
RU2392269C2 |
| DERIVATIVES OF ALKYLPIPERAZINE- AND ALKYLHOMOPIPERAZINECARBOXYLATES, OBTAINING THEM AND THEIR USE AS FERMENT FAAH INHIBITORS | 2005 |
|
RU2331637C2 |
| COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | 2018 |
|
RU2795572C2 |
| ARYLALKYLCARBAMATE DERIVATIVES, SYNTHESIS AND USE THEREOF IN THERAPY | 2004 |
|
RU2400472C2 |
| SULTAM-BASED COMPOUND AND METHOD OF USE THEREOF | 2017 |
|
RU2741915C2 |
| ASPARTATE PROTEASE INHIBITORS | 2006 |
|
RU2424231C2 |
| 1,3-DISUBSTITUTED 4-METHYL-1H-PYRROL-2-CARBOXAMIDES AND USE THEREOF FOR PREPARING DRUGS | 2007 |
|
RU2463294C2 |
| AMINOCARBONYLCARBAMATE COMPOUNDS | 2015 |
|
RU2688673C2 |
